Skip to main content

Table 1 Clinicopathological and sequencing characteristics

From: Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

Clinicopathological characteristics
Characteristic Discovery cohort Validation cohort
 Patients, N 94 24
 Tissue samples, N 106 24
 Age at RP, median (range) 65.7 (45.7–76.6) N/A
Tumor status
 Benign, N (%) 23 (21.7%) 8 (33.3%)
 Malignant, N (%) 83 (78.3%) 16 (66.6%)
Pathological Gleason score
 ≤ 7, N (%) 63 (75.9%) 9 (56.2)
 > 7, N (%) 20 (24.1%) 7 (43.7)
Pre-operative PSA (ng/ml)
 ≤ 10, N (%) 39 (47%) N/A
 >10, N (%) 39 (47%) N/A
 Unknown, N (%) 5 (6%) N/A
Pathological T-stage
 pT2, N (%) 51 (61.4%) 4 (25%)
 pT3, N (%) 31 (37.4%) 10 (62.5%)
 Unknown/pT4, N (%) 1 (1.2%) 2 (12.5%)
Biochemical recurrence status
 BCR, N (%) 28 (33.7%) 6 (37.5%)
 BCR-free, N (%) 53 (63.9%) 10 (62.5%)
 Unknown, N (%) 2 (2.4%) --
Median follow-up, months (range) 52.4 (17.6–178.9) N/A
Sequencing characteristics
Characteristic Discovery Cohort Validation cohort
Total reads in bam per sample, mean (SD) 76,688,094 (11,296,752) 304,920,301 (49,502,192)
Reads per sample mapped to hg38, mean (SD) 60,131,687 (7,869,239) 170,390,820 (16,853,739)
Unmapped read pairs per sample, mean (SD) 970,526 (280,812) 2,734,147 (421,428)
  1. RP radical prostatectomy, PSA prostate-specific antigen, SD standard deviation, Hg human genome